The Addition of Darolutamide to ADT Reduces Risk of Metastasis in Nonmetastatic CRPC

The Addition of Darolutamide to ADT Reduces Risk of Metastasis in Nonmetastatic CRPC

The Addition of Darolutamide to ADT Reduces Risk of Metastases in CRPCПодробнее

The Addition of Darolutamide to ADT Reduces Risk of Metastases in CRPC

Assessing the Role of Darolutamide in CRPCПодробнее

Assessing the Role of Darolutamide in CRPC

Understanding Nonmetastatic CRPC: An OverviewПодробнее

Understanding Nonmetastatic CRPC: An Overview

Darolutamide’s Role in Treating Nonmetastatic CRPCПодробнее

Darolutamide’s Role in Treating Nonmetastatic CRPC

ARASENS: the addition of darolutamide to ADT and docetaxel for the treatment of mHSPCПодробнее

ARASENS: the addition of darolutamide to ADT and docetaxel for the treatment of mHSPC

Dr. Fizazi on Darolutamide-Based Therapy in Nonmetastatic CRPCПодробнее

Dr. Fizazi on Darolutamide-Based Therapy in Nonmetastatic CRPC

ARAMIS: darolutamide in patients with nmCRPCПодробнее

ARAMIS: darolutamide in patients with nmCRPC

Darolutamide for nmCRPC: results of the ARAMIS trialПодробнее

Darolutamide for nmCRPC: results of the ARAMIS trial

FDA Approves Bayer's Nubeqa (Darolutamide) for Non-Metastatic Castration-Resistant Prostate CancerПодробнее

FDA Approves Bayer's Nubeqa (Darolutamide) for Non-Metastatic Castration-Resistant Prostate Cancer

Examining the Impact of Darolutamide on Pain and QoL in Patients With Nonmetastatic CRPCПодробнее

Examining the Impact of Darolutamide on Pain and QoL in Patients With Nonmetastatic CRPC

Dr. Shore on the Tolerability of Darolutamide in Nonmetastatic CRPCПодробнее

Dr. Shore on the Tolerability of Darolutamide in Nonmetastatic CRPC

ARAMIS trial of ODM-201 for high-risk non-metastatic castration-resistant prostate cancerПодробнее

ARAMIS trial of ODM-201 for high-risk non-metastatic castration-resistant prostate cancer

The ARAMIS Trial in M0 CRPCПодробнее

The ARAMIS Trial in M0 CRPC

Dr. Tagawa Discusses Darolutamide in CRPCПодробнее

Dr. Tagawa Discusses Darolutamide in CRPC

Interaction of darolutamide with substrates of CYPs and P-gpПодробнее

Interaction of darolutamide with substrates of CYPs and P-gp

Nonmetastatic CRPC: meeting an unmet needПодробнее

Nonmetastatic CRPC: meeting an unmet need

AUA2019 027IC: AUA CRPC Guidelines and Therapeutic Advances in Metastatic Prostate CancerПодробнее

AUA2019 027IC: AUA CRPC Guidelines and Therapeutic Advances in Metastatic Prostate Cancer

Dr. McDermott on Rationale for Darolutamide Plus ADT/Radiation in High-Risk Prostate CancerПодробнее

Dr. McDermott on Rationale for Darolutamide Plus ADT/Radiation in High-Risk Prostate Cancer

Achieving MFS and Improved Quality of Life in nmCRPC With DarolutamideПодробнее

Achieving MFS and Improved Quality of Life in nmCRPC With Darolutamide

Dr. Lee on the Role of Darolutamide in M0CRPCПодробнее

Dr. Lee on the Role of Darolutamide in M0CRPC

События